AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8561655 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (DRCA) with avocado (30% of total calories as fat, 75% of total fat from avocado)
Number of subjects: 16
Study 8561655 — intervention group
Group type: COMPARATOR
Intervention: Low-saturated fat diet without avocado (DRSA)
Number of subjects: 16
Study 2235803 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 0
Study 2235803 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 0
Study 2235803 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with significant bacteriuria
Number of subjects: 0
Study 2235803 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional belief of alkalinizing urine
Number of subjects: 0
Study 278688 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with supervised oral cleaning
Number of subjects: 248
Study 278688 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefaka (chewing stick) with supervised oral cleaning
Number of subjects: 248
Study 278688 — intervention group
Group type: COMPARATOR
Intervention: Instruction only (Control)
Number of subjects: 248
Study 31301476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 190
Study 31301476 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 190
Study 28410767 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 91
Study 28410767 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 91
Study 26094635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous microwave ablation with ethanol injection
Number of subjects: 49
Study 26094635 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided percutaneous microwave ablation without ethanol injection (control group)
Number of subjects: 49
Study 23489301 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 and 25 mg daily)
Number of subjects: 4168
Study 23489301 — intervention group
Group type: COMPARATOR
Intervention: Comparator therapies (other antidiabetic agents)
Number of subjects: 4168
Study 23489301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4168
Study 21732835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study 21732835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141
Study 19114436 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy for 12 months
Number of subjects: 44
Study 19114436 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 44
Study 19114436 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 44
Study 17337647 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program attendance
Number of subjects: 164
Study 17337647 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase (1 SD = 2.45 years)
Number of subjects: 164
Study 15569117 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Saccharomyces cerevisiae mannan detected using the Lille assay
Number of subjects: 493
Study 15569117 — intervention group
Group type: EXPERIMENTAL
Intervention: Different assays for anti-Saccharomyces cerevisiae mannan detection
Number of subjects: 493
Study 15569117 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance of anti-Saccharomyces cerevisiae mannan detection
Number of subjects: 493
Study 15569117 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of anti-Saccharomyces cerevisiae mannan in Crohn's disease vs. ulcerative colitis
Number of subjects: 493
Study 15569117 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of anti-Saccharomyces cerevisiae mannan with clinical features
Number of subjects: 493
Study 11416883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous BH4 (10 mg/kg)
Number of subjects: 15
Study 11416883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9595286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day for 16 weeks)
Number of subjects: 9
Study 9595286 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone washout
Number of subjects: 9
Study 7801667 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine 8 mg bid
Number of subjects: 24
Study 3050654 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg twice daily for 7 days
Number of subjects: 143
Study 3050654 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice daily for 7 days
Number of subjects: 143
Study 30665513 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised ground-based walking training (30–45 min, 2–3 times weekly for 8–10 weeks)
Number of subjects: 78
Study 30665513 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised ground-based walking training
Number of subjects: 78
Study 28374089 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 23
Study 28374089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 25945012 — intervention group
Group type: EXPERIMENTAL
Intervention: PDN+MTD 500 mg three times daily
Number of subjects: 135
Study 25945012 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX+MTD 500 mg three times daily
Number of subjects: 135
Study 25945012 — intervention group
Group type: EXPERIMENTAL
Intervention: MTD
Number of subjects: 135
Study 23438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Television report about the adverse health effects of WiFi (n=76)
Number of subjects: 147
Study 23438710 — intervention group
Group type: COMPARATOR
Intervention: Control film (n=71)
Number of subjects: 147
Study 21285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative model of depression care (problem-solving therapy, antidepressants, symptom monitoring, and relapse prevention)
Number of subjects: 472
Study 21285094 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 472
Study 21285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative model of depression care (for patients with depression recurrence)
Number of subjects: 472
Study 21285094 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 472
Study 19920418 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-injection technique
Number of subjects: 92
Study 19920418 — intervention group
Group type: COMPARATOR
Intervention: Single-injection technique
Number of subjects: 92
Study 17899571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (90 mg daily)
Number of subjects: 46
Study 14645938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco control intervention in grocery stores
Number of subjects: 7
Study 14645938 — intervention group
Group type: COMPARATOR
Intervention: Control stores (no intervention)
Number of subjects: 7
Study 12528731 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form information
Number of subjects: 787
Study 12528731 — intervention group
Group type: EXPERIMENTAL
Intervention: Long form information
Number of subjects: 787
Study 9372883 — intervention group
Group type: COMPARATOR
Intervention: Preoperative autologous blood donation (PAD)
Number of subjects: 120
Study 9372883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human erythropoietin (Epoetin alfa)
Number of subjects: 120
Study 8264923 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 12
Study 8264923 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 12
Study 8264923 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 12
Study 8264923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3514833 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated own mother's milk
Number of subjects: 36
Study 3514833 — intervention group
Group type: COMPARATOR
Intervention: Pooled pasteurized preterm milk
Number of subjects: 36
Study 3514833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (750 IU daily from 2nd week of life)
Number of subjects: 36
Study 3514833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-gla-protein
Number of subjects: 36
Study 3514833 — intervention group
Group type: EXPERIMENTAL
Intervention: Reexamination of infants (4 to 11 months after birth)
Number of subjects: 36
Study 29561245 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running (n=10)
Number of subjects: 19
Study 29561245 — intervention group
Group type: COMPARATOR
Intervention: Flat running (n=9)
Number of subjects: 19
Study 25762401 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound analgesia with bupivacaine
Number of subjects: 60
Study 25762401 — intervention group
Group type: COMPARATOR
Intervention: Placebo with free-saline solution
Number of subjects: 60
Study 23629583 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Range (LR) resistance training
Number of subjects: 26
Study 23629583 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Range (SR) resistance training
Number of subjects: 26
Study 23629583 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 23629583 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining effects on LR and SR groups
Number of subjects: 26
Study 22541040 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1383
Study 22541040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1383
Study 22541040 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and behavioral interventions
Number of subjects: 1383
Study 22541040 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and smoking reduction
Number of subjects: 1383
Study 19798074 — intervention group
Group type: COMPARATOR
Intervention: Diet (D)
Number of subjects: 328
Study 19798074 — intervention group
Group type: COMPARATOR
Intervention: Diet plus Exercise (D+E)
Number of subjects: 328
Study 19798074 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 328
Study 18634501 — intervention group
Group type: EXPERIMENTAL
Intervention: One intradermal injection of 0.1 ml (1 site) followed by two booster vaccinations of 0.1 ml (1 site) intradermally on days 0 and 3
Number of subjects: 0
Study 18634501 — intervention group
Group type: EXPERIMENTAL
Intervention: Three intradermal injections within one week
Number of subjects: 0
Study 18634501 — intervention group
Group type: COMPARATOR
Intervention: Three injections administered over 3-4 weeks with two booster vaccinations on days 0 and 3 one year later
Number of subjects: 0
Study 16060244 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (craniotomy or endovascular coil embolization)
Number of subjects: 615
Study 16060244 — intervention group
Group type: COMPARATOR
Intervention: Natural course observation (no surgical treatment)
Number of subjects: 615
Study 12370564 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration after heat exposure
Number of subjects: 8
Study 12370564 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration after exercise
Number of subjects: 8
Study 12370564 — intervention group
Group type: COMPARATOR
Intervention: No rehydration after heat exposure
Number of subjects: 8
Study 12370564 — intervention group
Group type: COMPARATOR
Intervention: No rehydration after exercise
Number of subjects: 8
Study 10559092 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA HFA (150, 300, or 600 microg/d)
Number of subjects: 514
Study 10559092 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA P‐12 (150, 300, or 600 microg/d)
Number of subjects: 514
Study 10559092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 9156925 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial signal‐averaged electrocardiogram (ALP) recording using HIPEC‐200HA in patients with PAF during IHD.
Number of subjects: 75
Study 9156925 — intervention group
Group type: COMPARATOR
Intervention: Atrial signal‐averaged electrocardiogram (ALP) recording using HIPEC‐200HA in healthy subjects.
Number of subjects: 75
Study 1770066 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase with dipyridamole or dilazep dihydrochloride
Number of subjects: 29
Study 1770066 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 29
Study 6181965 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sec standard interval (SI) followed by a 3 sec SI-TI delay and then by a 4.5, 5.0 or 5.5 sec test interval (TI)
Number of subjects: 0
Study 6181965 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sec pre-response interval (PRI) succeeding to TI
Number of subjects: 0
Study 6181965 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 8 sec TIs randomly presented in each trial
Number of subjects: 0
Study 31256356 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 12
Study 31256356 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (AGB)
Number of subjects: 12
Study 31256356 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical weight loss (MWL)
Number of subjects: 12
Study 30008589 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT (telbivudine) treatment
Number of subjects: 112
Study 30008589 — intervention group
Group type: COMPARATOR
Intervention: Observation group (no antiviral therapy)
Number of subjects: 112
Study 30008589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study 27779639 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise program (2-hour education session, five weekly 90-minute exercise training sessions, and home-based self-managed exercise program)
Number of subjects: 353
Study 27779639 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise program
Number of subjects: 353
Study 27779639 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 353
Study 25532087 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (bolus - 5 ml, lockout interval - 15 minutes, basal rate - 0 ml) with bupivacaine 0.08% and fentanyl 2 µg/ml
Number of subjects: 51
Study 25532087 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 51
Study 25532087 — intervention group
Group type: COMPARATOR
Intervention: CEA (10 ml/h) with bupivacaine 0.08% and fentanyl 2 µg/ml
Number of subjects: 51
Study 25532087 — intervention group
Group type: COMPARATOR
Intervention: CEA
Number of subjects: 51
Study 22227853 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary lactate (sLac)
Number of subjects: 12
Study 22227853 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase (sAA)
Number of subjects: 12
Study 22227853 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary chromogranin A (sCgA)
Number of subjects: 12
Study 19584823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG, thymoglobuline) on day+7, n=84
Number of subjects: 170
Study 19584823 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls), n=86
Number of subjects: 170
Study 17081656 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 isoenergetic meals fed hourly
Number of subjects: 16
Study 17081656 — intervention group
Group type: COMPARATOR
Intervention: 2 isoenergetic meals 3 h apart
Number of subjects: 16
Study 17081656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both feeding patterns
Number of subjects: 16
Study 15604943 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed imaging with tetrofosmin
Number of subjects: 131
Study 15604943 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed imaging with sestamibi
Number of subjects: 131
Study 15604943 — intervention group
Group type: COMPARATOR
Intervention: Administration of milk
Number of subjects: 131
Study 15604943 — intervention group
Group type: COMPARATOR
Intervention: Administration of milk plus water
Number of subjects: 131
Study 15604943 — intervention group
Group type: COMPARATOR
Intervention: Comparison between tetrofosmin and sestamibi
Number of subjects: 131
Study 12026752 — intervention group
Group type: EXPERIMENTAL
Intervention: Green paper questionnaire
Number of subjects: 0
Study 12026752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink paper questionnaire
Number of subjects: 0
Study 12026752 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue paper questionnaire
Number of subjects: 0
Study 12026752 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow paper questionnaire
Number of subjects: 0
Study 12026752 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored paper (any color)
Number of subjects: 0
Study 10327033 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomudex (raltitrexed)
Number of subjects: 0
Study 10327033 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) plus leucovorin (LV)
Number of subjects: 0
Study 8617079 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA 134a salbutamol sulfate
Number of subjects: 24
Study 8617079 — intervention group
Group type: COMPARATOR
Intervention: CFC 11/12 salbutamol
Number of subjects: 24
Study 1782715 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic/steroid mixture with alternate day dressings
Number of subjects: 10
Study 1782715 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotic/steroid mixture with sump filling
Number of subjects: 10
Study 6168426 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP (nitrogen mustard, vincristine, procarbazine and prednisone)
Number of subjects: 0
Study 6168426 — intervention group
Group type: COMPARATOR
Intervention: MOP (the same combination without prednisone)
Number of subjects: 0
Study 6168426 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐MOPP (MOPP plus bleomycin at low dosage)
Number of subjects: 0
Study 6168426 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 0
Study 6168426 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPP (chlorambucil substituted for nitrogen mustard)
Number of subjects: 0
Study 6168426 — intervention group
Group type: EXPERIMENTAL
Intervention: CVB combination (CCNU, vinblastine and bleomycin)
Number of subjects: 0
Study 31483962 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 798
Study 31483962 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 798
Study 31483962 — intervention group
Group type: COMPARATOR
Intervention: Foam sclerotherapy
Number of subjects: 798
Study 31483962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness model favoring laser ablation
Number of subjects: 798
Study 28631408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic SAE (modified SAE)
Number of subjects: 21
Study 28631408 — intervention group
Group type: COMPARATOR
Intervention: SAE (control group)
Number of subjects: 21
Study 26062633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 10°C for 10 minutes
Number of subjects: 10
Study 26062633 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (ACT) - low-intensity cycling for 10 minutes
Number of subjects: 10
Study 23722897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravoxel incoherent motion (IVIM) MR imaging for nasopharyngeal carcinoma (NPC)
Number of subjects: 83
Study 23722897 — intervention group
Group type: COMPARATOR
Intervention: Intravoxel incoherent motion (IVIM) MR imaging for post‐chemoradiation fibrosis
Number of subjects: 83
Study 23722897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off values for IVIM parameters
Number of subjects: 83
Study 21338797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed calves bedded with sand previously positive for M. bovis (n=6)
Number of subjects: 12
Study 21338797 — intervention group
Group type: COMPARATOR
Intervention: Unexposed controls bedded with control sand (n=6)
Number of subjects: 12
Study 21338797 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed group sand
Number of subjects: 12
Study 21338797 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of mycoplasma detection in exposed calves
Number of subjects: 12
Study 21338797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 12
Study 19034466 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial (A-M) trans-tibia approach
Number of subjects: 55
Study 19034466 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral (A-L) trans-tibia approach
Number of subjects: 55
Study 18089334 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir oral solution (900 mg)
Number of subjects: 23
Study 18089334 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir tablets (900 mg)
Number of subjects: 23
Study 18089334 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir oral solution
Number of subjects: 23
Study 18089334 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir tablets
Number of subjects: 23
Study 18089334 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir oral solution vs tablets
Number of subjects: 23
Study 18089334 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir oral solution and tablets
Number of subjects: 23
Study 10990571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernix caseosa
Number of subjects: 0
Study 10990571 — intervention group
Group type: COMPARATOR
Intervention: Eucerin(R)
Number of subjects: 0
Study 10990571 — intervention group
Group type: COMPARATOR
Intervention: Aquaphor(R)
Number of subjects: 0
Study 10990571 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 0
Study 10990571 — intervention group
Group type: COMPARATOR
Intervention: Control skin
Number of subjects: 0
Study 8791950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d. (cohort A)
Number of subjects: 120
Study 8791950 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg b.d., clarithromycin 250 mg b.d., tetracycline 300 mg b.d. (cohort B)
Number of subjects: 120
Study 1538013 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushed venous sheath between each biopsy attempt
Number of subjects: 51
Study 1538013 — intervention group
Group type: COMPARATOR
Intervention: Flushed venous sheath only at the time of initial placement
Number of subjects: 51
Study 1538013 — intervention group
Group type: EXPERIMENTAL
Intervention: More than six biopsy attempts
Number of subjects: 51